$2.80
0.36% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Polypid Ltd Stock price

$2.80
-0.05 1.75% 1M
-0.49 14.89% 6M
-0.24 7.89% YTD
-1.70 37.78% 1Y
-147.20 98.13% 3Y
-567.20 99.51% 5Y
-567.20 99.51% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.01 0.36%
ISIN
IL0011326795
Symbol
PYPD
Sector
Industry

Key metrics

Market capitalization $28.53m
Enterprise Value $20.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.71
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-28.03m
Free Cash Flow (TTM) Free Cash Flow $-22.04m
Cash position $15.64m
EPS (TTM) EPS $-3.83
P/E forward negative
Short interest 0.53%
Show more

Is Polypid Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Polypid Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Polypid Ltd forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Polypid Ltd forecast:

Buy
100%

Financial data from Polypid Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.22 5.22
22% 22%
-
- Research and Development Expense 23 23
41% 41%
-
-26 -26
25% 25%
-
- Depreciation and Amortization 1.62 1.62
11% 11%
-
EBIT (Operating Income) EBIT -28 -28
23% 23%
-
Net Profit -29 -29
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polypid Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polypid Ltd Stock News

Neutral
GlobeNewsWire
2 days ago
New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology
Neutral
GlobeNewsWire
12 days ago
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
Neutral
Seeking Alpha
18 days ago
PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capi...
More Polypid Ltd News

Company Profile

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID–500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

Head office Israel
CEO Dikla Akselbrad
Employees 59
Founded 2008
Website www.polypid.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today